Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yi Shen Jian Gu is a traditional Chinese medicine (TCM) formula available as granules or gel. It is primarily used to manage aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) in postmenopausal women with early-stage breast cancer undergoing aromatase inhibitor therapy. The formulation consists of a combination of 12 herbs, including Radix rehmanniae Preparata (ShuDiHuang), Semen cuscutae (TuSiZi), Rhizoma cyperi (XiangFu), Rhizoma chuanxiong (ChuanXiong), Rhizoma corydalis (YanHuSuo), and Caulis trachelospermi (LuoShiTeng). The exact full composition is currently under patent protection and not fully disclosed[2]. Clinical studies have shown that YSJG significantly improves musculoskeletal symptoms compared to placebo and is well-tolerated with mild side effects such as grade 1 nausea and grade 2 diarrhea[1][2]. Its mechanism of action likely involves multi-target modulation typical for TCM formulas but specific molecular targets are not established.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yi Shen Jian Gu.